As a result, AChE inhibition and BuChE inhibition have been identified as significant targets for the efficient therapy of AD by increasing the availability of acetylcholine in brain areas and decreasing Aβ accumulation [9]. This evidence concerns the gene ACHE and Alzheimer disease.